dehydroepiandrosterone has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "DHEA treatment did not alter disease progression or survival in SOD1-G93A rats." | 5.38 | Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012) |
| "DHEA treatment did not alter disease progression or survival in SOD1-G93A rats." | 1.38 | Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, JP | 1 |
| O'Brien, LC | 1 |
| Brohawn, DG | 1 |
| Hayes-Punzo, A | 1 |
| Mulcrone, P | 1 |
| Meyer, M | 1 |
| McHugh, J | 1 |
| Svendsen, CN | 1 |
| Suzuki, M | 1 |
| Eisen, A | 1 |
| Pearmain, J | 1 |
| Stewart, H | 1 |
3 other studies available for dehydroepiandrosterone and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Pharmacological properties of microneurotrophin drugs developed for treatment of amyotrophic lateral sclerosis.
Topics: Absorption, Physiological; Amyotrophic Lateral Sclerosis; Animals; ATP Binding Cassette Transporter, | 2016 |
Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Dehydroepiandrosterone; Disea | 2012 |
Dehydroepiandrosterone sulphate (DHEAS) concentrations and amyotrophic lateral sclerosis.
Topics: Adult; Age Distribution; Age Factors; Aged; Amyotrophic Lateral Sclerosis; Dehydroepiandrosterone; F | 1995 |